This protocol applies to primary lymphoma of bone presenting in the context of systemic anaplastic large cell lymphoma (ALCL) — specifically where stage I disease has not been completely resected, the presentation is not limited to isolated skin involvement, and there is no central nervous system involvement. The patient is younger than 18 years at diagnosis.
Systemic ALCL with not completely resected stage I disease (not isolated skin) and without CNS involvement in a pediatric patient drives selection of a structured multi-phase chemotherapy approach. Both the systemic ALCL subtype and the patient's age under 18 are essential eligibility criteria for this first-line protocol.
The regimen begins with a structured prephase, followed by a series of alternating multi-agent chemotherapy courses. The overall framework involves multiple distinct cycle types administered in a defined sequence — complete agent selection, cycle structure, and clinical management details are contained in the full protocol.
Full regimen, alternating cycle specifics, and clinical decision guidance are accessible via the link below.